Is LQDA a Buy or a Sell? The Bull and Bear Case (2026)
Last updated October 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Liquidia Corporation (LQDA) rests on Yutrepia commercial ramp, now in PAH: Yutrepia revenue has climbed every quarter since launch: about $92 million in the fourth quarter of 2025, $133 million in the first quarter of 2026, $172 million in the second and a preliminary $223 million of net product sales in the third. The bear case rests on liquidia is highly concentrated: the vast majority of revenue comes from a single drug, Yutrepia, now limited to one indication (PAH) after the settlement, so any slowdown in uptake, reimbursement pressure, or manufacturing or supply issue would hit results disproportionately. Analysts covering it publish targets from $33.00 to $70.00 against a $34.35 price, so even the professionals disagree by 68% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Liquidia Corporation is a specialty pharmaceutical company focused on treating pulmonary hypertension. Its lead product, Yutrepia (treprostinil inhalation powder), is a dry-powder inhaled prostacyclin that received final FDA approval in May 2025 and launched commercially in June 2025. It was approved for pulmonary arterial hypertension (PAH) and for pulmonary hypertension associated with interstitial lung disease (PH-ILD), but under the October 2026 settlement with United Therapeutics Liquidia filed to remove the PH-ILD indication and stopped promoting the drug for it, so its labeled use is being narrowed to PAH. The company is also developing L606, an investigational sustained-release inhaled treprostinil dosed twice daily with a next-generation nebulizer, now in the registrational Phase 3 Re-Spire study, and it terminated its promotional agreement for treprostinil injection as part of the settlement. The operating picture is a fast single-product ramp that has turned into real profit. Revenue rose from about $54 million in the third quarter of 2025 to about $133 million in the first quarter of 2026 and about $172 million in the second quarter, when net income reached roughly $75 million, and trailing twelve-month revenue is now about $451 million with net income near $139 million. Preliminary third-quarter 2026 Yutrepia net product sales were about $223 million, in line with the roughly $214 million revenue consensus, with full results expected around November 3, 2026. The legal picture changed sharply in two weeks. On September 30, 2026 the Delaware district court ruled that two claims of United Therapeutics' U.S. Patent No. 11,826,327 (covering PH-ILD use) were valid and infringed, and the stock fell steeply. On October 14 the companies settled six matters: Liquidia agreed to net payments of about $380.7 million (about $175 million to United Therapeutics within 30 business days, two installments of about $72.7 million due by January 31 and April 30, 2027, and about $60.3 million to parties in the treprostinil injection antitrust litigation), agreed not to appeal, and gave up the PH-ILD label. The shares jumped on the news but at about $34 remain down roughly 49% over one month and 58% over three months, while still up about 9% year to date and 47% over one year.
The bull case: what would have to be true for $70.00
The most optimistic published target on LQDA is $70.00, +103.8% from the $34.35 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Yutrepia commercial ramp, now in PAH
Yutrepia revenue has climbed every quarter since launch: about $92 million in the fourth quarter of 2025, $133 million in the first quarter of 2026, $172 million in the second and a preliminary $223 million of net product sales in the third. Earlier the company reported more than 4,500 unique prescriptions and a conversion rate at or above 85%. With the PH-ILD indication being removed under the settlement, future growth has to come from share gains in PAH, and analysts' 2026 revenue estimate sits near $717 million with 2027 near $762 million.
2. Profitability, then a large settlement bill
Net income reached roughly $53 million in the first quarter of 2026 and about $75 million in the second, with trailing twelve-month net income near $139 million, operating margin around 50% and gross margin above 90%. Cash was a preliminary $396 million at September 30, 2026. The settlement calls for about $380.7 million in payments through April 2027, which management expects to fund from Yutrepia sales and existing cash, and analysts' estimates show a loss of about $0.28 per share in the fourth quarter of 2026 as the charge lands.
3. The end of the United Therapeutics litigation
The October 14 settlement resolves six matters with mutual releases and no admission of liability, and Liquidia agreed not to appeal the September 30 ruling on the '327 patent. That removes the open-ended legal risk that hung over the stock since launch, at the cost of the PH-ILD market and a cash payment equal to a large share of a year's revenue.
4. L606 and pipeline optionality
L606, a sustained-release inhaled treprostinil prodrug dosed twice daily, is in the registrational Phase 3 Re-Spire study and represents the next potential product beyond Yutrepia. Success would extend the franchise and reduce single-product dependence, which matters more now that Yutrepia's label is narrower, though marketing approval is not assured and any launch is years away.
The bear case: what would have to be true for $33.00
The most pessimistic published target is $33.00, -3.9% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Liquidia Corporation is worth if the risks below bite instead of the drivers above.
Liquidia is highly concentrated: the vast majority of revenue comes from a single drug, Yutrepia, now limited to one indication (PAH) after the settlement, so any slowdown in uptake, reimbursement pressure, or manufacturing or supply issue would hit results disproportionately. The settlement removes the PH-ILD market, which had been part of the growth case, and commits about $380.7 million in payments through April 2027, which will weigh on cash and on reported earnings around the fourth quarter of 2026. The company still competes directly against United Therapeutics' larger, entrenched Tyvaso franchise. The stock has been extremely volatile, with a 52-week range of about $22 to $94 and a drop of roughly 49% in the past month, and the latest reported quarter (second-quarter 2026 EPS of $0.74) came in below the $0.85 estimate. Analysts' forward estimates show growth slowing to under 10% in 2027, and L606 approval is not guaranteed.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding LQDA already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on LQDA
8 analysts cover LQDA, with an average target of $54.38 (+58.3% against $34.35) and a split of 6 buy, 2 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the LQDA forecast and price target page.
How is LQDA valued? (as of October 2026)
Snapshot for LQDA as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$451M (Q2 2026 ~$172M)
- Q3 2026 Yutrepia sales (preliminary): ~$223M (consensus revenue ~$214M)
- Net income (TTM): ~$139M (EPS ~$1.39)
- Margins: Gross ~93%, operating ~50%, net ~31%
- P/E (trailing / forward): ~25x / ~16x
- Cash: ~$396M preliminary (Sep 30, 2026); debt ~$183M
- Settlement payments: ~$381M through April 2027
- Market cap: ~$3.1B (about $34 a share)
After the patent loss and settlement, Liquidia trades at roughly 7 times trailing revenue and about 16 times forward earnings, far below the near $7 billion valuation it carried in July 2026. The analyst mean target of about $54 (8 analysts) sits well above the price, but forward estimates now assume a PAH-only Yutrepia growing to roughly $762 million of revenue in 2027, and the settlement payments will absorb much of the next several quarters of cash generation.
How do you decide if LQDA is a buy?
Rather than asking whether LQDA is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold LQDA indirectly through an index or sector ETF before adding more.
What would change your mind on LQDA
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Yutrepia commercial ramp, now in PAH stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: liquidia is highly concentrated: the vast majority of revenue comes from a single drug, Yutrepia, now limited to one indication (PAH) after the settlement, so any slowdown in uptake, reimbursement pressure, or manufacturing or supply issue would hit results disproportionately fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the LQDA stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about LQDA against your real portfolio and see your actual exposure before deciding.
Investing in Liquidia Corporation with AI
Connect the broker you already use and ask Walnut's AI how LQDA fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is LQDA a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Yutrepia commercial ramp, now in PAH, with revenue (ttm) at ~$451M (Q2 2026 ~$172M). The bear case rests on liquidia is highly concentrated: the vast majority of revenue comes from a single drug, Yutrepia, now limited to one indication (PAH) after the settlement, so any slowdown in uptake, reimbursement pressure, or manufacturing or supply issue would hit results disproportionately. Analysts covering it are spread from $33.00 to $70.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell LQDA?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Liquidia is highly concentrated: the vast majority of revenue comes from a single drug, Yutrepia, now limited to one indication (PAH) after the settlement, so any slowdown in uptake, reimbursement pressure, or manufacturing or supply issue would hit results disproportionately. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $33.00, -3.9% from the $34.35 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for LQDA?
+
Yutrepia commercial ramp, now in PAH. Yutrepia revenue has climbed every quarter since launch: about $92 million in the fourth quarter of 2025, $133 million in the first quarter of 2026, $172 million in the second and a preliminary $223 million of net product sales in the third. The most optimistic analyst target on LQDA is $70.00, +103.8% from the $34.35 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for LQDA?
+
Liquidia is highly concentrated: the vast majority of revenue comes from a single drug, Yutrepia, now limited to one indication (PAH) after the settlement, so any slowdown in uptake, reimbursement pressure, or manufacturing or supply issue would hit results disproportionately. The settlement removes the PH-ILD market, which had been part of the growth case, and commits about $380.7 million in payments through April 2027, which will weigh on cash and on reported earnings around the fourth quarter of 2026. The company still competes directly against United Therapeutics' larger, entrenched Tyvaso franchise. The stock has been extremely volatile, with a 52-week range of about $22 to $94 and a drop of roughly 49% in the past month, and the latest reported quarter (second-quarter 2026 EPS of $0.74) came in below the $0.85 estimate. Analysts' forward estimates show growth slowing to under 10% in 2027, and L606 approval is not guaranteed. The most pessimistic published target is $33.00, -3.9% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Liquidia Corporation do?
+
Liquidia Corporation is a specialty pharmaceutical company focused on treating pulmonary hypertension.
What would have to change for LQDA to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Yutrepia commercial ramp, now in PAH) stalling in the reported numbers rather than in the narrative, the risk above (liquidia is highly concentrated: the vast majority of revenue comes from a single drug, Yutrepia, now limited to one indication (PAH) after the settlement, so any slowdown in uptake, reimbursement pressure, or manufacturing or supply issue would hit results disproportionately) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Liquidia Corporation do?
+
Liquidia is a specialty pharmaceutical company focused on pulmonary hypertension. Its lead product, Yutrepia, is an inhaled dry-powder form of treprostinil for pulmonary arterial hypertension (its PH-ILD indication is being removed under the October 2026 settlement), and it is also developing L606, a longer-acting inhaled treprostinil candidate.
Is LQDA profitable?
+
Yes. Driven by Yutrepia's launch, Liquidia earned about $53 million in the first quarter of 2026 and about $75 million in the second, with trailing twelve-month net income near $139 million. Analysts expect a loss of about $0.28 per share in the fourth quarter of 2026 as the settlement payments are recorded.
What is Yutrepia?
+
Yutrepia is Liquidia's inhaled dry-powder treprostinil product. It received final FDA approval in May 2025 for PAH and PH-ILD and launched in June 2025, and under the October 2026 settlement its label is being narrowed to PAH. Preliminary third-quarter 2026 net product sales were about $223 million.
Walnut is informational, not investment advice, and gives no verdict on LQDA. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.